Remove tag financing
article thumbnail

STAT+: Steward Health Care has deal to sell doctor network to UnitedHealth

STAT

Troubled hospital operator Steward Health Care, grappling with a financial crisis that’s engulfed its eight Massachusetts hospitals, has moved to shore up its finances by striking a deal to sell its nationwide physician network to insurance giant UnitedHealth’s Optum Care unit. Continue to STAT+ to read the full story…

Hospitals 135
article thumbnail

Smart pharmaceutical and healthcare labels: Lets trace medicines from its origin

Roots Analysis

It is worth noting that smart labels contain a transponder code which can be read by sophisticated devices, including radio frequency identification device (RFID) tags and near-field communication (NFC) chips. While most smartphones can read NFC chips, RFID tags can only be read by specialized receivers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PharmaShots Weekly Snapshots (April 24 - 28, 2023)

PharmaShots

Difficile Infection Date: Apr 27, 2023 | Tags: Seres Therapeutics, Nestlé Health Science, Vowst, C.

FDA 56
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. 79% of risk-sharing agreements are finance-based According to GlobalData’s risk-sharing database, over 1,000 RSAs were made in the last decade across 28 countries and roughly 100 companies.

FDA 105
article thumbnail

STAT+: Pharmalittle: Some employers cut insurance coverage for weight loss drugs; U.S. urges ADHD pill makers to boost production

STAT

The outlays are straining the finances of some plans, including those funded by employers. The Besides the $26,500 annual price tag, treatment could cost U.S.  The reimbursement cuts, along with restrictions that other employers are implementing, mark the financial downside of the drugs’ medical triumph.

article thumbnail

Second unanimous FDA adcomm vote boosts bluebird bio

pharmaphorum

Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8 million price tag, saying its ability to help patients reach sustained transfusion independence justified its high price. Beti-cel offers another potentially curative treatment for a much broader range of patients.

FDA 58
article thumbnail

ICER says bluebird bio’s $2.1m gene therapy is cost-effective

pharmaphorum

million price tag. ” There’s a lot riding on the outcome of the beti-cel advisory committee meeting and FDA review, as bluebird revealed last month that its future as an ongoing business was uncertain unless it can raise additional financing. The post ICER says bluebird bio’s $2.1m

FDA 63